Key Takeaways
- Merck stock fell 9.5% in the week ended Nov. 20, slightly worse than the S&P 500’s 8.6% drop, after it stopped work on the blood cancer drug nemtabrutinib and healthcare stocks sold off.
- That leaves Eli Lilly’s Jaypirca with one fewer rival, and a German court sided with Merck against Halozyme on under-the-skin Keytruda.
- Analysts still see Merck’s 2027 earnings back at 2025’s level.
- At about 16x forward earnings, the dip looks like a buy if Keytruda’s 2028 patent loss turns out as mild as management expects.
Merck (MRK) fell 9.5% in the week ended Nov. 20, against 8.6% for the S&P 500, though it’s still up 27% in 2026. Its one piece of bad news, a drug still in development, is good news for Eli Lilly (LLY). Its other news, a court win over Halozyme Therapeutics (HALO), went Merck’s way.
A small loss, and a win in Germany
After the close on Tuesday, Nov. 17, Merck stopped developing nemtabrutinib, an experimental blood cancer pill it picked up in its $2.7 billion ArQule deal. An independent review of a Phase 3 trial found the drug’s benefits may not outweigh its risks. Next to Keytruda’s $31.7 billion of 2025 sales, that’s a small loss. And it’s a gain for Lilly, whose Jaypirca is the same kind of drug and sold $228 million in the third quarter, up 59%.
On Thursday, Nov. 19, a German appeals court overturned the preliminary injunction Halozyme won in December 2025 against under-the-skin Keytruda there. A separate Dutch ruling from October, which restricts the drug in eight European markets, isn’t affected. Halozyme’s growth doesn’t hinge on Merck: its royalties rose 44% to $341 million last quarter on other partners’ drugs.
Merck fell anyway, losing 3.9% on Nov. 18 as managed care stocks sank and 3.6% on Nov. 19, when nine in 10 S&P 500 stocks fell as Anthropic began trading. On Friday, it rose 0.7% while the S&P 500 lost 3.7%, after its drug sac-TMT met the main survival goal of a late-stage gastroesophageal cancer trial, though it missed a second goal.
TIKR tracks 28 analysts on Merck. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Merck, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Merck’s Analyst Ratings
Keytruda’s 2028 patent loss is still the test
Third-quarter sales rose 5% to $18.1 billion, and Merck raised the low end of its 2026 sales guidance, putting the range at $66.8-$67.3 billion. On Nov. 17, it raised its quarterly dividend to $0.88 from $0.85. CFO Caroline Litchfield calls Keytruda’s U.S. patent loss in 2028 “really more of a hill on the overall revenues of our company,” and analysts agree. Consensus normalized EPS falls to $2.79 this year on acquisition charges, then gets back to $8.96 in 2027.

A cheaper Merck, if the hill stays a hill
Merck traded at about 18x forward earnings before the drop and about 16x now, against a five-year average of 14x.

The $162 consensus target sits about 21% above the Nov. 20 close of $133.72.

On 2028’s $9.93 consensus EPS, that target is about 16x, so the stock doesn’t need a higher multiple. The estimates just have to hold.
The dip looks like a buy. The market did most of the selling, and nemtabrutinib was never part of the Keytruda math that drives Merck’s earnings. The risk is 2027, which Litchfield calls “another year of investment.” Merck gives 2027 guidance with its fourth-quarter results in early February, and EPS guidance near $8.96 would show the hill is still a hill.
So what is Merck stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Merck could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!